Tuesday, 17 October 2017 07:30 AM
LONDON, UK / ACCESSWIRE / October 17, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Aratana Therapeutics, Inc. (NASDAQ: PETX), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=PETX. The Company announced on October 14, 2017, that it is launching ENTYCE® (Capromorelin oral solution) and making it commercially available to veterinarians in the United States for appetite stimulation in dogs. For immediate access to our complimentary reports, including today's coverage, register for free now at:
http://protraderdaily.com/register/
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on PETX. Go directly to your stock of interest and access today's free coverage at:
http://protraderdaily.com/optin/?symbol=PETX
ENTYCE Provides the First Therapeutic Based on the Natural Physiology of Appetite
Commenting on the launch, Ernst Heinen, DVM, PhD, Chief Development Officer of Aratana Therapeutics, stated that improper food intake inhibits the overall health of the dog and negatively impacts dog's quality of life. The Company stated that nutrition is considered very important for pets, where veterinarians and pet owners often use appetite as a fifth vital sign and go to great lengths to address inappetence. Ernst added that ENTYCE was developed specifically to stimulate appetite and provides the first therapeutic based on the natural physiology of appetite.
CVM Approved Aratana's Prior-Approval Supplement for Transfer and Scale-up of ENTYCE Manufacturing
On April 25, 2017, Aratana Therapeutics announced that it met with the US Food and Drug Administration Center for Veterinary Medicine (CVM) regarding the proposed manufacturing transfer of ENTYCE®. In May 2016, CVM approved Entyce for appetite stimulation in dogs. Entyce showed to be effective in improving the appetite of dogs compared to placebo.
What is ENTYCE?
ENTYCE is a ghrelin receptor agonist that mimics the effect of ghrelin (the hunger hormone). Like naturally occurring ghrelin, ENTYCE binds to specific cell receptors and affects signaling in the hypothalamus to cause the feeling of hunger, which in turn, leads to food intake. The Company noted that it is the only FDA-approved therapeutic designed to safely and effectively stimulate appetite in dogs.
ENTYCE is for use in dogs only. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation.
Field Study for Testing ENTYCE
In June 2016, controlled field study was conducted, and 244 dogs were evaluated for safety when administered either ENTYCE or a vehicle control (solution minus Capromorelin) at a dose of 3 mg/kg once daily for 4 days. Enrolled dogs had a reduced or absent appetite for a minimum of 2 days and had various medical conditions. The adverse reactions observed were diarrhea, vomiting, hypersalivation, abdominal discomfort, flatulence, and nausea and were reported in less than 1% dogs.
The Company Launched Galliprant for Treatment of Canine Osteoarthritis
Earlier this year in January, Aratana Therapeutics, in collaboration with Elanco Animal Health, launched a medication, Galliprant® (grapiprant tablets), for the management of pain and inflammation associated with canine osteoarthritis (OA).
Appetite Stimulation Problems in Dogs
Inappetence is a condition caused by a multitude of chronic diseases or acute conditions. Inappetence may present as decreased appetite, complete lack of appetite, or altered eating patterns. Signs may include weight loss, muscle wasting, lip smacking, or a change from normal behavior.
About Aratana Therapeutics, Inc.
Founded in 2010, Aratana Therapeutics is a pet therapeutics company focused on licensing, developing, and commercializing innovative pet therapeutics for dogs and cats. The Company's goal is to provide veterinarians and pet owners with new therapeutics that are driven by science and specifically made for pets, and focuses efforts in the areas of pain, inappetence, cancer, viral diseases, allergy, and other conditions. Aratana Therapeutics is headquartered in Leawood, Kansas.
Last Close Stock Review
On Monday, October 16, 2017, the stock closed the trading session at $6.55, climbing 4.80% from its previous closing price of $6.25. A total volume of 1.23 million shares have exchanged hands, which was higher than the 3-month average volume of 250.90 thousand shares. Aratana Therapeutics' stock price rallied 4.63% in the last one month and 15.72% in the past six months. The stock currently has a market cap of $281.72 million.
Pro-Trader Daily:
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily